[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,313
  • Shares Outstanding, K 72,299
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,800 K
  • EBIT $ -67 M
  • EBITDA $ -65 M
  • 60-Month Beta -0.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.56

Options Overview Details

View History
  • Implied Volatility 267.44% (+94.47%)
  • Historical Volatility 67.05%
  • IV Percentile 88%
  • IV Rank 24.37%
  • IV High 791.65% on 11/20/25
  • IV Low 98.55% on 01/21/26
  • Expected Move (DTE 27) 0.3655 (30.97%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 186
  • Volume Avg (30-Day) 386
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 87,901
  • Open Int (30-Day) 85,694
  • Expected Range 0.8145 to 1.5455

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 4
  • High Estimate $-0.17
  • Low Estimate $-0.31
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) +58.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +7.27%
on 06/09/26
1.4800 -20.27%
on 06/04/26
-0.0700 (-5.60%)
since 05/18/26
3-Month
1.0700 +10.28%
on 03/24/26
2.2370 -47.25%
on 04/20/26
+0.0100 (+0.85%)
since 03/18/26
52-Week
0.8719 +35.34%
on 11/21/25
2.9900 -60.54%
on 10/06/25
-0.7300 (-38.22%)
since 06/18/25

Most Recent Stories

More News
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking...

BMEA : 1.1800 (-1.67%)
Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6) Persistence...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients  COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from...

BMEA : 1.1800 (-1.67%)
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.1800 (-1.67%)
Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.1800 (-1.67%)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.3458
2nd Resistance Point 1.3047
1st Resistance Point 1.2423
Last Price 1.1800
1st Support Level 1.1388
2nd Support Level 1.0977
3rd Support Level 1.0353

See More

52-Week High 2.9900
Fibonacci 61.8% 2.1809
Fibonacci 50% 1.9310
Fibonacci 38.2% 1.6810
Last Price 1.1800
52-Week Low 0.8719

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.